ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1420

Alignment Between Rheumatology and Neurology of Nomenclature for Peripheral Nervous System Neuropathies

Ghaith Noaiseh1, George Sarka2, Anahita Deboo3, Arun Varadhachary4, Robert Fox5, Matthew Baker6, Stamatina Danielides7, Eduardo de Sousa8, Julie Frantsve Hawley9, Brent Goodman10, Katherine Hammitt9, Jennifer King11, Steven Mandel12, Pantelis Pavlakis13, Daniel Wallace14, Robert Hal Scofield15, Nancy Carteron16 and Steven Carsons17, 1University of Kansas Medical Center, Kansas City, KS, 2UCLA, Laguna Hills, CA, 3Temple University, Philadelphia, 4Washington University in St. Louis, St. Louis, MO, 5Rheumatology Clinic, San Diego, CA, 6Stanford University, Menlo Park, CA, 7Vcu, Glen Allen, VA, 8Mercy, Moore, OK, 9Sjogren's Foundation, Reston, VA, 10Mayo Clinic, Scottsdale, AZ, 11UCLA, Los Angeles, CA, 12Hofstra, Hempstead, 13Hospital for Special Surgery, New York, NY, 14Cedars Sinai Medical Center, Studio City, CA, 15Oklahoma Medical Research Foundation, Oklahoma City, OK, 16University of California, Berkeley & San Francisco, Angwin, CA, 17NYU Long Island School of Medicine, Mineola, NY

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, Education, education, medical, neurology, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Sjögren's Syndrome – Basic & Clinical Science Poster I

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: The Sjögren’s Foundation Clinical Practice Guidelines for Peripheral Nervous System (PNS) diagnosis, management and treatment in Sjögren’s brought to the fore a major issue with communication between clinicians in rheumatology and those in neurology. Nomenclature used by the two specialties often differs, hindering multi-specialty collaboration for clinical management, clinical trials, and clinical practice guidelines. 

Our goal was to bring neurologists and rheumatologists together to understand, define and align nomenclature used by specialists in connection with PNS involvement in Sjögren’s.

Methods: The Topic Review Group (TRG) for the Sjögren’s PNS Clinical Practice Guidelines was comprised of both rheumatologists and neurologists. The group met regularly by email, phone, and zoom to identify differences in terminology and definitions typically used by neurologists and rheumatologists and develop an aligned nomenclature to be used across these disciplines. The TRG nomenclature discussions involved terms for the PNS categories of mononeuropathy, large fiber neuropathy, small fiber neuropathy, demyelinating polyradiculoneuropathy, ganglionopathy, vasculitic neuropathy, and autonomic nervous system neuropathy.

Results: An aligned nomenclature was created defining terminology used to describe specific peripheral neurological manifestations of Sjögren’s, including commonly used synonymous terms that could be used interchangeably. Definitions were crafted that rheumatologists and neurologists could agree upon. Twelve terms used to describe seven PNS categories were fully delineated. Additional information was included for each category on patient presentation, possible etiologies and diagnoses, pathologies, and evaluation.

Conclusion: Clear communication between specialists involved in Sjögren’s is paramount to good patient care. By identifying the nomenclature used by both specialties and ensuring alignment on what each specialty means by its use, collaboration among specialists is facilitated, clinical care improved, and involvement of non-traditional specialists needed for patient care and in clinical trials can be increased with greater success.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: G. Noaiseh: Janssen, 1, Novartis, 1; G. Sarka: None; A. Deboo: None; A. Varadhachary: Argenx, 2, Biogen, 2, 6; R. Fox: Novartis, 2; M. Baker: None; S. Danielides: None; E. de Sousa: Alnylam, 6, Argenx, 1, 6, AstraZeneca, 1, 6, CSL Behring, 6, Grifols, 1, 6, UCB, 6; J. Frantsve Hawley: Publication, 9, Quip, 1; B. Goodman: None; K. Hammitt: None; J. King: None; S. Mandel: None; P. Pavlakis: None; D. Wallace: None; R. Scofield: Johnson and Johnson Innovative Medicine, 1, Merck, 1; N. Carteron: Bristol-Myers Squibb(BMS), 1, 2, HealthWell Foundation, 4; S. Carsons: Kiniksa, 1.

To cite this abstract in AMA style:

Noaiseh G, Sarka G, Deboo A, Varadhachary A, Fox R, Baker M, Danielides S, de Sousa E, Frantsve Hawley J, Goodman B, Hammitt K, King J, Mandel S, Pavlakis P, Wallace D, Scofield R, Carteron N, Carsons S. Alignment Between Rheumatology and Neurology of Nomenclature for Peripheral Nervous System Neuropathies [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/alignment-between-rheumatology-and-neurology-of-nomenclature-for-peripheral-nervous-system-neuropathies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/alignment-between-rheumatology-and-neurology-of-nomenclature-for-peripheral-nervous-system-neuropathies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology